is ketamine fda approved for treatment-resistant depression? esketamine is, ketamine is not
“So ketamine is FDA approved for the treatment of treatment refractory depression.”
a guest, director of a dual diagnosis addiction clinic at Stanford (psychiatrist) said on Huberman Lab, 2026-11-09, at 2:04:49. hear it in context → the speaker cited: the FDA.
first, the part that holds
the fda has approved a drug made from ketamine for treatment-resistant depression. it is esketamine nasal spray, approved march 5, 2019, and the current label also allows it to be used on its own.
what we found when we went and looked
we read the fda record. the treatment-resistant depression approval belongs to esketamine, the (S)-enantiomer of racemic ketamine, given as a nasal spray under a restricted program (NDA 211243, approved march 5, 2019). the current esketamine label, updated september 22, 2026, covers treatment-resistant depression in adults "as monotherapy or in conjunction with an oral antidepressant." ketamine itself is the injectable racemic drug first approved in 1970, and its current label lists only anesthetic uses: no depression indication and no other psychiatric indication. the approval is real, but the speaker attached it to the wrong molecule, and that difference matters to anyone offered ketamine at an infusion clinic or as a compounded product.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| ketamine is fda approved for the treatment of treatment-resistant (treatment-refractory) depression | misattributed | the only fda approval for treatment-resistant depression in this family is esketamine nasal spray (NDA 211243, march 5, 2019), which the label describes as "the (S)-enantiomer of racemic ketamine." the approval is real. the speaker attached it to racemic ketamine, which does not hold it. [1][2][3] |
| racemic ketamine (the injectable drug used in infusion clinics) carries an fda indication for depression | false | the ketamine hydrochloride injection label (revised 2/2026, initial u.s. approval 1970) lists only these uses: "as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation; for the induction of anesthesia prior to the administration of other general anesthetic agents; as a supplement to other anesthetic agents." it has no psychiatric indication. infusion-clinic use for depression is off-label. we checked one manufacturer's label. other generic ketamine labels share the same reference listing, but we did not read each one. [3] |
| the approved product for treatment-resistant depression is esketamine, with broader use than when first approved | confirmed | the 2019 approval package gives the indication as "in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression (TRD) in adults." the current label adds use "as monotherapy" and a second indication: depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, alongside an oral antidepressant. [1][2] |
| the fda approval comes with access restrictions | confirmed | per the label, esketamine "is only available through a restricted program" (a REMS) and "is only dispensed and administered in healthcare settings." it carries a boxed warning on sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors in younger patients. the label also states it is "not approved as an anesthetic agent." [1] |
| the fda has flagged compounded ketamine sold for psychiatric use | confirmed | the fda compounding risk alerts index lists two alerts: oct 10, 2023 ("potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders") and feb 16, 2022 (compounded ketamine nasal spray). we read the index page with these titles and dates. the full alert pages did not load in this session. [4] |
both directions
for the speaker: the speaker is close. esketamine is one half of the racemic ketamine molecule, and its label lists \"Initial U.S. Approval: 1970 (ketamine),\" which ties the two together. the fda did approve it for treatment-resistant depression in 2019, and the label has since grown to cover monotherapy and depression with acute suicidal ideation. in conversation, many clinicians say \"ketamine\" when they mean esketamine, so the speaker's point that the fda has endorsed a ketamine-type treatment for hard-to-treat depression is correct in substance.
against: the claim names the wrong drug. racemic ketamine, the iv, im, oral and compounded drug sold at most ketamine clinics, has only anesthetic indications on its fda label. the fda has issued two compounding risk alerts about ketamine products marketed for psychiatric disorders. the approved product is a specific nasal spray at fixed doses, given under observation in certified healthcare settings through a REMS. its label states it is \"not approved as an anesthetic agent,\" which shows the fda treats the two products as distinct. a listener who hears \"ketamine is fda approved\" could reasonably assume off-label infusions or take-home compounded lozenges carry the same fda backing. they do not.
what this cannot say
a label shows what the fda approved. it does not show whether off-label racemic ketamine works for depression, and we did not assess that evidence here. we read one ketamine injection label, the current esketamine label and the 2019 approval package. we did not read every generic ketamine label. the full text of the two compounding alerts did not load in this session, so we rely only on their titles and dates from the fda index. we also cannot tell from the clip whether the speaker meant esketamine and simply said \"ketamine.\"
the medication pages behind this check
sources, each one fetched and read
- National Library of Medicine, DailyMed. Esketamine hydrochloride nasal spray, prescribing information, updated September 22, 2026. What we read there: Indicated for "treatment-resistant depression (TRD) in adults, as monotherapy or in conjunction with an oral antidepressant". Describes esketamine as "the (S)-enantiomer of racemic ketamine". States it is "not approved as an anesthetic agent" and "only available through a restricted program" (REMS) in healthcare settings. Initial U.S. approval: 1970 (ketamine). Fetched 2026-11-10 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed
- FDA Center for Drug Evaluation and Research. Approval package, NDA 211243Orig1s000 (esketamine nasal spray, 28 mg), 2019. What we read there: Generic name: esketamine. Approval date: March 5, 2019 (the year's last digit is cut off on the cover page). Indicated "in conjunction with an oral antidepressant, for the treatment of treatment-resistant depression (TRD) in adults." Fetched 2026-11-10 (HTTP 200). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000Approv.pdf
- National Library of Medicine, DailyMed. Ketamine hydrochloride injection, prescribing information, revised 2/2026. What we read there: Indications: "as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation; for the induction of anesthesia prior to the administration of other general anesthetic agents; as a supplement to other anesthetic agents." Initial U.S. approval 1970. No depression or psychiatric indication. Fetched 2026-11-10 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8b01c77-620d-4734-a771-b8524b65bcca
- U.S. Food and Drug Administration. Compounding risk alerts (index page). What we read there: Lists an October 10, 2023 alert: "FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders". Also lists a February 16, 2022 alert on compounded ketamine nasal spray. Fetched 2026-11-10 (HTTP 200). https://www.fda.gov/drugs/human-drug-compounding/compounding-risk-alerts
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam